CANCER VACCINES & CUBA VACCINE

CANCER VACCINES – CUBA VACCINE

Ganglioside GM3(Neu5Gc) is a glycosphingolipid that exist in some cancer tissues which is indentified as a tumor-specific antigen. A vaccine named as Racotumumab (Vaxira) has been developed in Cuba, against cancer tissues which contain this antigen.

The aim of Racotumumab cancer vaccine is to teach the immune system to recognize this antigen on cell membranes and identify these cells as cancerous tissue, therefore trigger an immune response for their elimination. GM3(Neu5Gc) does not exist on healthy tissues which renders the vaccine as side-effects free.

Cancers that Racotumumab is effective on are, these(1-9):

• Small cell lung cancer
• Breast cancer
• Food pipe (oesophagus/esophagus) cancer
• Stomach cancer
• Colon cancer
• Rectum cancer
• Pancreas cancer
• Liver cancer
• Kidney cancer
• Bladder cancer
• Testicular cancer
• Uterus cancer
• Prostate cancer
• Thyroid cancer
• Sarcomas
• Wilms tumor
• Ewing sarcoma
• Neuroblastoma

Another cancer vaccine that has been developed in Cuba is the anti VEGF. Certain countries have been issued permits for the use of these vaccines.

Racotumumab and anti VEGF cancer vaccine is applied to the patients with advanced stage small cell lung cancer which is unresponsive to either chemotherapy or radiotherapy (10). We can also evaluate and prescribe the vaccination to certain patients.

There are ongoing clinical trials and case studies concerning the use of Racotumumab vaccine on other types of cancers with the expectation of licensing availability.

The most important advantage of Cuban vaccines is; they lack serious side effects while increasing the quality of life of the patient or providing longevity.